Abstracts tagged "outcome measures and randomized trials"

Abstract Number: 1508 • 2013 ACR/ARHP Annual Meeting
How Well Are The Assessment Of Spondyloarthritis International Society (ASAS) / Outcome Measures In Rheumatology (OMERACT) Core Outcome Sets For Ankylosing Spondylitis Implemented In Randomized Clinical Trials? A Systematic Literature Review
Wilson Bautista-Molano^1,2, Victoria Navarro-Compán¹, Robert Landewé³ and Désirée van der Heijde⁴, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Universidad Militar Nueva Granada, Bogotá, Colombia, ³Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) has selected a core set of variables to include as standardized endpoints in clinical trials and clinical…
Abstract Number: 2646 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Tai Chi Mind-Body Exercise for the Treatment of Fibromyalgia
John B. Wong¹ and Chenchen Wang², ¹Medicine/Clinical Decision Making, Tufts Medical Center, Boston, MA, ²Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Although fibromyalgia is associated with substantial annual direct medical and indirect productivity costs, the cost-effectiveness of treatments for fibromyalgia remains understudied. A randomized…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].